Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Current Deferred Revenue (2016 - 2021)

Arcadia Biosciences filings provide 8 years of Current Deferred Revenue readings, the most recent being $63000.0 for Q2 2021.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $63000.0 in Q2 2021 year-over-year; TTM through Jun 2021 was $63000.0, a N/A change, with the full-year FY2020 number at $8000.0, down 80.95% from a year prior.
  • Current Deferred Revenue hit $63000.0 in Q2 2021 for Arcadia Biosciences, roughly flat from $63000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.0 million in Q4 2017 to a low of $8000.0 in Q4 2020.
  • Median Current Deferred Revenue over the past 5 years was $88000.0 (2018), compared with a mean of $310875.0.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 96.81% in 2019 and later soared 270.59% in 2021.
  • Arcadia Biosciences' Current Deferred Revenue stood at $1.0 million in 2017, then crashed by 90.4% to $96000.0 in 2018, then crashed by 56.25% to $42000.0 in 2019, then plummeted by 80.95% to $8000.0 in 2020, then surged by 687.5% to $63000.0 in 2021.
  • The last three reported values for Current Deferred Revenue were $63000.0 (Q2 2021), $63000.0 (Q1 2021), and $8000.0 (Q4 2020) per Business Quant data.